Best Read Articles on COVID-19 Drug-Related News in 2021
The attention-getting articles about COVID-19 included news about Pfizer's booster and the FDA's rejection Zyesami (aviptadil) for treatment of COVID-19-related respiratory failure.
FDA Rejects EUA for COVID-19 Respiratory Failure Therapy
The FDA didn’t have enough data to assess the risks and benefits of Zyesami.
Amber Specialty, Hy-Vee to Dispense Regeneron Monoclonal Antibody for COVID-19
Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.
Pfizer Submits EUA for COVID-19 Vaccine Booster for All Adults
The FDA had previously issued an EUA for those over the age of 65 and those at high risk for severe COVID-19 or exposure to the virus.
Concerns About Childhood COVID-19 Vaccines Persist, Despite FDA Committee OK
Some have expressed concerns about the risk of myocarditis and unknown longer-term side effects.
FDA Issues EUA for Pfizer COVID-19 Vaccine for Children
The dose is one-third of the dose given to people 12 years and older.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 3rd 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 3rd 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
